IP Library Patent Application 10538315
Patent Application
App. No. 10/538,315

Wound dressings comprising vanadate complexed with organic ligands

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/538,315
Abstract

The invention relates to wound dressings comprising a tyrosine phosphatase inhibitor that stimulates collagen deposition and fibroblast proliferation thereby accelerating wound healing. Preferred tyrosine phosphatase inhibitors are complexes of vanadate and peroxovanadate with organic ligands.

Claims (14)

1 . A wound dressing comprising a complex of vanadate with an organic ligand, wherein said complex stimulates collagen deposition and fibroblast proliferation.

2 . A wound dressing according to claim 1 , wherein the complex of vanadate with an organic ligand is a complex of vanadate with a nitrogen ligand, an oxo-anionic ligand, or a combination thereof.

3 . A wound dressing according to claim 1 , wherein the complex of vanadate with an organic ligand is a complex of vanadate with a π-donor ligand.

4 . A wound dressing according to claim 1 wherein the complex of vanadate with an organic ligand is a complex of vanadate with a bidentate ligand.

5 . A wound dressing according to claim 1 , wherein the organic ligand is selected from the group consisting of:

6 . A wound dressing according to claim 5 , wherein the organic ligand comprises picolinate or dimethylamido.

7 . The wound dressing according to claim 1 , wherein the wound dressing does not comprise a growth factor.

8 . A wound dressing for topical application to a wound comprising a tyrosine phosphatase inhibitor.

9 . A wound dressing according to claim 8 , wherein the tyrosine phosphatase inhibitor is dispersed in or on a solid sheet of wound contacting material, or in a layer of foam such as polyurethane foam, or in a gel or ointment.

10 . A wound dressing according to claim 9 , wherein the tyrosine phosphatase inhibitor is dispersed in or on a solid sheet of biodegradable sheet material that provides sustained release of the tyrosine phosphatase into the wound.

11 . A method for manufacturing a medicament for increasing the rate of wound healing comprising applying to a wound a tyrosine phosphatase inhibitor other than orthovanadate, wherein the complex stimulates collagen deposition and fibroblast proliferation.

12 . The method according to claim 11 , wherein the medicament is a wound dressing.

13 . The method according to claim 11 , wherein the wound is a chronic wound.

14 . The method according to claim 13 wherein the chronic wound is selected from the group consisting of venous ulcer, pressure sore and decubitis ulcer.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2013
From: J.P. MORGAN EUROPE LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 031506/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2010
From: JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT IP CO. B.V.
Reel/Frame 024563/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2010
From: ETHICON, INC.; JOHNSON & JOHNSON; JOHNSON & JOHNSON MEDICAL LIMITED; JOHNSON & JOHNSON MEDICAL B.V.; JANSSEN PHARMACEUTICA N.V.; CILAG AG; CILAG HOLDING AG; JEVCO LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.; SYSTAGENIX WOUND MANAGEMENT IP CO. B.V.
Reel/Frame 024563/0368 →
SECURITY AGREEMENT Recorded Jan 30, 2009
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: J.P. MORGAN EUROPE LIMITED
Reel/Frame 022177/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2009
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 022071/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2006
From: TROTTER, PATRICK
To: ETHICON, INC.
Reel/Frame 017279/0468 →